Real-Life Treatment Paradigms Show Adalimumab Is Cost-Effective for the Management of Ulcerative Colitis

Table 5

Maintenance probabilities of patients on adalimumab over time.

Cycle #	Rate of response of UC patients [23]	Chronic pouchitis patients (ADA not available arm) [40, 41]	Chronic pouchitis patients (ADA available arm)	Rate of response of patient’s dose escalated [42]
0	86.8	62.6	53.2	93.8
1	73.3	61.2	52.0	80.5
2	66.5	59.9	50.9	73.7
3	62.0	58.6	49.8	69.1
4	58.7	57.3	48.7	65.8
5	56.2	56.1	47.7	63.2
6	54.1	54.9	46.7	61.1
7	52.4	53.7	45.6	59.4
8	50.9	52.5	44.6	57.8
9	49.6	51.4	43.7	56.5
10	48.5	50.3	42.8	55.3
11	47.5	49.2	41.8	54.3
12	46.5	48.1	40.9	53.3
13	45.7	47.0	40.0	52.5
14	45.0	46.0	39.1	51.7
15	44.3	45.0	38.3	51.0
16	43.6	44.0	37.4	50.3
17	43.0	43.1	36.6	49.7
18	42.4	42.1	35.8	49.1
19	41.9	41.2	35.0	48.5
20	41.4	40.2	34.2	48.0

To calculate the response probability for patients with chronic pouchitis who had been previously exposed to and failed adalimumab, a 15% discount was taken from the probability of response of patients with chronic pouchitis who had never been exposed to ADA.
These maintenance probabilities are based on Crohn’s disease patient information.